Skip to content
TrialScanner

NCT03091192

Savolitinib vs. Sunitinib in MET-driven PRCC.

Phase 3Active, not recruitingAZNLead

Registry record

Lead sponsor
AstraZeneca
Conditions
Carcinoma; Carcinoma, Renal Cell; Kidney Neoplasms; Urologic Neoplasms; Kidney Diseases
Primary completion
Aug 18, 2019Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03091192 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03091192: Savolitinib vs. Sunitinib in... | TrialScanner